Purchase Order 75F40124P00202
Award Date
6/4/24
Potential Completion Date
9/26/29
Potential Value
$781K
Federal Agency
Food and Drug Administration
Awardee
Illumina, Inc.
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Diego, CA 92122, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc. for an ILLUMINA NEXTSEQ2000 SEQUENCING SYSTEM. The contract has a ceiling value of $576,928.00 and a completion date of July 20, 2026. Illumina is a manufacturer of sequencing and array-based solutions for genetic and genomic analysis, and has previously received prime federal contract and subcontract awards from agencies such as the National Institutes of Health (NIH), Centers for...
This is a firm fixed price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc. for preventative maintenance services on Illumina's NextSeq 2000 and NextSeq 500 sequencing systems. The total ceiling value of the contract is $417,372.48 and the ultimate completion date is September 24, 2026. Illumina is a manufacturer of genetic sequencing and genomic analysis instruments and software. This contract does not have a set-aside designation. Illumina has previously...
This firm fixed-price purchase order was awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents, to provide a diagnostic check and system upgrades for the MiSeq Whole Genome Sequencer at six FDA laboratories. The $84,733.20 contract has a completion date of December 31, 2022 and was sole-sourced to Illumina due to the proprietary nature of the MiSeq technology. Illumina has previously provided sequencing systems,...
This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of genetic sequencing instruments and reagents. The contract has a ceiling value of $924,805.20 and a period of performance ending on March 23, 2019. The award is for the provision of high-throughput sequencing equipment and services, with no set-aside designation. Illumina has a history of supporting genomic sequencing and analysis requirements across various...
This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for the service and maintenance of one Illumina MiSeq sequencing system, with a ceiling value of $34,972.40 and a performance period ending on September 24, 2024. Illumina, a for-profit organization and manufacturer of goods, has been awarded numerous prime federal contracts and...
This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract is for NEXTSEQ 500 comprehensive plan service maintenance for two NextSeq 500 sequencing systems at the FDA's location in Berwyn Heights, Maryland. The contract has a ceiling value of $265,801.32 and a period of performance through September 30, 2021. This contract does not have a...
This is a firm fixed price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a manufacturer of sequencing and array-based solutions for genetic and genomic analysis. The contract is for the delivery of a "HIGH-THROUGHPUT DESKTOP SEQUENCER WITH DATA ANALYSIS SYSTEM" and has a ceiling value of $426,000.30. There is no set-aside designation for this contract. Illumina has previously provided a range of sequencing systems, reagents, and...
This is a firm fixed-price purchase order contract awarded by the Food and Drug Administration (FDA) to Illumina, Inc., a leading manufacturer of genetic sequencing and genomic analysis technologies. The contract, valued at $70,930.76, is for preventive maintenance and repair services for Illumina's MiSeq genetic sequencing instruments. The contract has an ultimate completion date of August 31, 2025 and does not utilize any set-aside designations. Illumina is a specialized technology provider...
This is a $142,142.04 firm fixed-price purchase order awarded by the Food and Drug Administration (FDA) to Illumina, Inc. for an annual maintenance agreement on Illumina's NextSeq2000 genetic sequencing instruments. The contract has a period of performance of 5 years, from June 6, 2024 to June 6, 2029. Illumina is a manufacturer of genetic sequencing systems, reagents, and bioinformatics solutions, and has provided these types of products and services to federal agencies such as the National...
This firm fixed-price delivery order, valued at $201,939.00, was awarded by the Food and Drug Administration (FDA) to Illumina, Inc. for preventative maintenance services on MiSeq benchtop sequencing instruments. The award does not have a set-aside designation. Illumina is a manufacturer of genetic sequencing systems and has a history of supporting genomic research and diagnostics across multiple federal agencies. This award indicates Illumina is providing maintenance services to help ensure the...